CA2453442A1 - Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases - Google Patents

Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases Download PDF

Info

Publication number
CA2453442A1
CA2453442A1 CA002453442A CA2453442A CA2453442A1 CA 2453442 A1 CA2453442 A1 CA 2453442A1 CA 002453442 A CA002453442 A CA 002453442A CA 2453442 A CA2453442 A CA 2453442A CA 2453442 A1 CA2453442 A1 CA 2453442A1
Authority
CA
Canada
Prior art keywords
recited
ocular
subject
combretastatin
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002453442A
Other languages
French (fr)
Other versions
CA2453442C (en
Inventor
David Sherris
Mark Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxi Gene Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2453442A1 publication Critical patent/CA2453442A1/en
Application granted granted Critical
Publication of CA2453442C publication Critical patent/CA2453442C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention is directed to the administration of vascular targetin g agents, particularly a tubulin binding agent, for the treatment of ocular neovascularization, ocular tumors, and conditions such as diabetic retinopathy, retinopathy of prematurity, retinoblastoma and macular degeneration.

Claims (95)

1. A method for the treatment of ocular disease, the method comprising the steps of:
a) preparing a dosage comprising a pharmaceutically effective dosage of a tubulin binding agent;
b) administering the pharmaceutically effective dosage to a subject in need thereof.
2. The method as recited in claim 1, wherein said tubulin binding agent is combretastatin A4.
3. The method as recited in claim 1, wherein said tubulin binding agent is combretastatin A4 prodrug.
4. The method as recited in claim 1, wherein said ocular disease may include neovascularization of the retina, neovascularization of the choroid and neovascularization of ocular tumors.
5. The method as recited in claim 1, wherein said ocular disease may include diabetic retinopathy, retinopathy of prematurity, and retinoblastoma .
6. The method as recited in claim 1, wherein said ocular disease may include neovascularization of the cornea and macular degeneration.
7. The method as recited in claim 1, wherein said pharmaceutically effective dosage is administered non-systemically to the eye of said subject.
8. The method as recited in claim 1, wherein said pharmaceutically effective dosage is administered non-systemically to the eye via intravitreal injection, sub-conjunctival injection, peri-ocular injection, sub-Tenon's injection, via ophthalmic drops, via ophthalmic gel, via ophthalmic ointment, via iontophoresis and via ocular implant and/or ocular insert.
9. The method as recited in claim 7, wherein said pharmaceutically effective dosage administered non-systemically comprises an amount of combretastatin A4 prodrug in the range of from approximately 0.1 mg/ml to approximately 100 mg/ml.
10. The method as recited in claim 1, wherein said pharmaceutically effective dosage is systemically administered to said subject.
11. The method as recited in claim 1, wherein said pharmaceutically effective dosage is administered parenterally.
12. The method as recited in claim 10, wherein said pharmaceutically effective dosage administered systemically comprises an amount of combretastatin A4 prodrug in the range of from approximately 0.1 mg/m2 to approximately 120 mg/m2.
13. The method as recited in claim 1, wherein said subject is a mammal.
14. A pharmaceutical medicament for the treatment of ocular disease, comprising a therapeutically effective amount of a tubulin binding agent for reducing ocular neovascularization in association with a pharmaceutically acceptable carrier, excipient, diluent or adjuvant for administration to a subject in need thereof.
15. The pharmaceutical medicament as recited in claim 14, wherein said tubulin binding agent is combretastatin A4.
16. The pharmaceutical medicament as recited in claim 14, wherein said tubulin binding agent is combretastatin A4 prodrug.
17. The pharmaceutical medicament as recited in claim 14, wherein said ocular disease may include neovascularization of the retina, neovascularization of the choroid and neovascularization of ocular tumors.
18. The pharmaceutical medicament as recited in claim 14, wherein said ocular disease may include diabetic retinopathy, retinopathy of prematurity, and retinoblastoma.
19. The pharmaceutical medicament as recited in claim 14, wherein said ocular disease may include neovascularization of the cornea and macular degeneration.
20. The pharmaceutical medicament as recited in claim 14, wherein said therapeutically effective amount is administered non-systemically to the eye of said subject.
21. The pharmaceutical medicament as recited in claim 13, wherein said therapeutically effective amount is administered non-systemically to the eye via intravitreal injection, sub-conjunctival injection, peri-ocular injection, sub-Tenon's injection, via ophthalmic drops, via iontophoresis and via ocular implant and/or ocular insert.
22. The pharmaceutical medicament as recited in claim 20, wherein said pharmaceutically effective dosage administered non-systemically comprises an amount of combretastatin A4 prodrug in the range of from approximately 0.1 mg/ml to approximately 100 mg/ml.
23. The pharmaceutical medicament as recited in claim 14, wherein said pharmaceutically effective dosage is systemically administered to said subject.
24. The pharmaceutical medicament as recited in 14, wherein said pharmaceutically effective dosage is administered parenterally.
25. The pharmaceutical medicament as recited in claim 23, wherein said pharmaceutically effective dosage administered systemically comprises an amount of combretastatinA4 prodrug in the range of from approximately 0.1 mg/m2 to approximately 120 mg/m2.
26. The pharmaceutical medicament as recited in claim 14, wherein said subject is a mammal.
27. A method of treating or preventing ocular neovascularization in a subject, the method comprising administering to said subject a pharmaceutically effective dosage of a tubulin binding agent.
28. The method as recited in claim 27, wherein said tubulin binding agent is combretastatin A4.
29. The method as recited in claim 27, wherein said tubulin binding agent is combretastatin A4 prodrug.
30. The method as recited in claim 27, wherein said ocular neovascularization may include neovascularization of the retina, neovascularization of the choroid and neovascularization of ocular tumors.
31. The method as recited in claim 27, wherein said pharmaceutically effective dosage is administered non-systemically to the eye of said subject.
32. The method as recited in claim 27, wherein said pharmaceutically effective dosage is administered non-systemically to the eye via intravitreal injection, sub-conjunctival injection, peri-ocular injection, sub-Tenon's injection, via ophthalmic drops, via iontophoresis and via ocular implant and/or ocular insert.
33. The method as recited in claim 31, wherein said pharmaceutically effective dosage administered non-systemically comprises an amount of combretastatin A4 prodrug in the range of from approximately 0.1 mg/ml to approximately 100 mg/ml.
34. The method as recited in claim 27, wherein said pharmaceutically effective dosage is systemically administered to said subject.
35. The method as recited in 30, wherein said pharmaceutically effective dosage is administered parenterally.
36. The method as recited in claim 34, wherein said pharmaceutically effective dosage administered systemically comprises an amount of combretastatin A4 prodrug in the range of from approximately 0.1 mg/m2 to approximately 120 mg/m2.
37. The method as recited in claim 30, wherein said subject is a mammal.
38. A method of treating or preventing ocular tumors, the method comprising administering a pharmaceutically effective dosage of a tubulin binding agent to a subject in need thereof.
39. The method as recited in claim 38, wherein said tubulin binding agent is combretastatin A4.
40. The method as recited in claim 38, wherein said tubulin binding agent is combretastatin A4 prodrug.
41. The method as recited in claim 38, wherein said ocular tumors may include retinoblastoma, primary ocular lymphoma, choroidal melanoma and intraocular melanoma.
42. The method as recited in claim 38, wherein said pharmaceutically effective dosage is administered non-systemically to the eye of said subject.
43. The method as recited in claim 38, wherein said pharmaceutically effective dosage is administered non-systemically to the eye via intravitreal injection, sub-conjunctival injection, peri-ocular injection, sub-Tenon's injection, via ophthalmic drops, via ophthalmic gel, via ophthalmic ointment, via iontophoresis and via ocular implant and/or ocular insert.
44. The method as recited in claim 42, wherein said pharmaceutically effective dosage administered non-systemically comprises an amount of combretastatin A4 prodrug in the range of from approximately 0.1 mg/ml to approximately 100 mg/ml.
45. The method as recited in claim 38, wherein said pharmaceutically effective dosage is systemically administered to said subject.
46. The method as recited in 38, wherein said pharmaceutically effective dosage is administered parenterally.
47 47. The method as recited in claim 45, wherein said pharmaceutically effective dosage administered systemically comprises an amount of combretastatin A4 prodrug in the range of from approximately 0.1 mg/m2 to approximately 120 mg/m2.
48. The method as recited in claim 38, wherein said subject is a mammal.
49. A pharmaceutical composition comprising a therapeutically effective amount of a tubulin binding agent for administration to a subject suffering from an ocular disease.
50. The pharmaceutical composition as recited in claim 49, wherein said tubufin binding agent is combretastatin A4.
51. The pharmaceutical composition as recited in claim 49, wherein said tubulin binding agent is combretastatin A4 prodrug.
52. The pharmaceutical composition as recited in claim 49, wherein said ocular disease may include neovascularization of the retina, neovascularization of the choroid and ocular tumors.
53. The pharmaceutical medicament as recited in claim 49, wherein said ocular disease may include diabetic retinopathy, retinopathy of prematurity, and retinoblastoma.
54. The pharmaceutical medicament as recited in claim 49, wherein said ocular disease may include neovascularization of the cornea and macular degeneration.
55. The pharmaceutical composition as recited in claim 49, wherein said therapeutically effective amount of said tubulin binding agent is administered non-systemically to the eye of said subject.
56. The pharmaceutical composition as recited in claim 49, wherein said composition is non-systemically administered to the eye of said subject via intravitreal injection, sub-conjunctival injection, peri-ocular injection, sub-Tenon's injection, via ophthalmic drops, via ophthalmic gel, ophthalmic ointment, via iontophoresis and via ocular implant and/or insert.
57. The pharmaceutical composition as recited in claim 55, wherein said therapeutically effective amount administered non-systemically comprises an amount of combretastatin A4 prodrug in the range of from approximately 0.1 mg/ml to approximately 100 mg/ml.
58. The pharmaceutical composition as recited in claim 49, wherein said therapeutically effective amount of combretastatin A4 prodrug is systemically administered to said subject.
59. The pharmaceutical composition as recited in claim 49, wherein said therapeutically effective amount of combretastatin A4 prodrug is administered parenterally.
60. The pharmaceutical composition as recited in claim 58, wherein said therapeutically effective amount said administered systemically comprises an amount of combretastatin A4 prodrug in the range of from approximately 0.1 mg/m2 to approximately 120 mg/m2.
61. The pharmaceutical composition as received in claim 49, wherein said subject is a mammal.
62. A pharmaceutical dosage form which comprises a therapeutically effective amount of combretastatin A4 prodrug and a pharmaceutically acceptable carrier or excipient for treating ocular diseases in a subject via administration of said dosage form to said subject.
63. The pharmaceutical dosage form as recited in claim 62, wherein said ocular diseases may include neovascularization of the retina, neovascularization of the choroid and ocular tumors.
64. The pharmaceutical dosage form as recited in claim 62, wherein said ocular diseases may include diabetic retinopathy, retinopathy of prematurity, and retinoblastoma.
65. The pharmaceutical dosage form as recited in claim 62, wherein said ocular disease may include neovascularization of the cornea and macular degeneration.
66. The pharmaceutical dosage form as recited in claim 62, wherein said therapeutically effective amount of combretastatin A4 prodrug is administered non-systemically to the eye of said subject.
67. The pharmaceutical dosage form as recited in claim 62, wherein said composition is non-systemically administered to the eye of said subject via intravitreal injection, sub-conjunctival injection, peri-ocular injection, sub-Tenon's injection, via ophthalmic drops, via ophthalmic gel, via ophthalmic ointment, via iontophoresis and via ocular implant and/or insert.
68. The pharmaceutical dosage form as recited in claim 66, wherein said therapeutically effective amount administered non-systemically comprises an amount of combretastatin A4 prodrug in the range of from approximately 0.1 mg/ml to approximately 100 mg/ml.
69. The pharmaceutical dosage form as recited in claim 62, wherein said therapeutically effective amount of combretastatin A4 prodrug is systemically administered to said subject.
70. The pharmaceutical dosage form as recited in claim 62, wherein said therapeutically effective amount of combretastatin A4 prodrug is administered parenterally.
71. The pharmaceutical dosage form as recited in claim 69, wherein said therapeutically effective amount administered systemically comprises an amount of combretastatin A4 prodrug in the range of from approximately 0.1 mg/m2 to approximately 120 mg/m2.
72. The pharmaceutical dosage form as received in claim 64, wherein said subject is a mammal.
73. A method of treating ocular diseases by administering a tubulin binding agent to the eye of a subject in need thereof in a dose sufficient to achieve a concentration of the tubulin binding agent in the eye in the range between approximately 1 nM to approximately 100 mM
of aqueous humour tissue.
74. The method as recited in claim 73, wherein said ocular diseases may include neovascularization of the retina, neovascularization of the choroid and neovascularization of ocular tumors.
75. The method as recited in claim 73, wherein said ocular diseases may include diabetic retinopathy, retinopathy of prematurity, and retinoblastoma.
76. The method as recited in claim 73, wherein said ocular diseases may include neovascularization of the cornea and macular degeneration.
77. The method as recited in claim 73, wherein said tubulin binding agent is combretastatin A4 prodrug.
78. The methods as recited in claim 73, wherein said tubulin binding agent is administered to the eye of said subject via intravitreal injection, sub-conjunctival injection, peri-ocular injection, sub-Tenon's injection, via ophthalmic drops, via ophthalmic gel, via ophthalmic ointment, via iontophoresis and via ocular implant and/or ocular insert.
79. A pharmaceutical composition for topical administration to the eye of subject afflicted with an ocular disease, comprising a tubulin binding agent in association with a pharmaceutically acceptable carrier, excipient, diluent or adjuvant for administration to a subject in need thereof.
80. The pharmaceutical composition as recited in claim 79, wherein said tubulin binding binding agent is combretastatin A4 prodrug.
81. The pharmaceutical composition as recited in claim 79, wherein said ocular disease may include neovascularization of the retina, neovascularization of the choroid and neovascularization of ocular tumors.
82. The pharmaceutical composition as recited in claim 79, wherein said ocular disease may include diabetic retinopathy, retinopathy of prematurity, and retinoblastoma.
83. The pharmaceutical composition as recited in claim 79, wherein said ocular diseases may include neovascularization of the cornea and macular degeneration.
84. The pharmaceutical composition as recited in claim 79, wherein said composition is administered non-systemically to the eye of said subject.
85. A pharmaceutical composition for topical administration to the eye of a subject afflicted with an ocular disease, the composition comprising in a suspension, emulsion or solution:
(a) an amount of CA4P in the range of from approximately 0.1 mg/ml to approximately 100 mg/ml;
(b) approximately 5 mg/ml carboxymethylcellulose; and (c) approximately 9mg/ml NaCl.
86. The pharmaceutical composition as recited in claim 85, wherein said composition has a final pH in the range of from approximately 6.6 to 8.6, osmolarity in the range of from approximately 291-492 mosmol/kg H2O and viscosity in the range of from approximately 50-66 mPa.s.
87. The pharmaceutical composition as recited in claim 85, wherein said ocular disease may include neovascularization of the retina, neovascularization of the choroid and neovascularization of ocular tumors.
88. The pharmaceutical composition as recited in claim 85, wherein said ocular disease may include diabetic retinopathy, retinopathy of prematurity, and retinoblastoma.
89. The pharmaceutical composition as recited in claim 85, wherein said ocular diseases may include neovascularization of the cornea and macular degeneration.
90. The pharmaceutical composition as recited in claim 85, wherein said composition is administered non-systemically to the eye of said subject.
91. A pharmaceutical composition for the treatment or prevention of ocular diseases and ocular tumors, comprising a therapeutically effective amount of combretastatin A4 prodrug in association with a pharmaceutically acceptable carrier, excipient, diluent or adjuvant for administration to a subject in need thereof.
92. The pharmaceutical composition as recited in claim 91, wherein said therapeutically effective amount of combretastatin A4 prodrug is non-systemically administered to the eye of said subject via intravitreal injection, sub-conjunctival injection, peri-ocular injection, sub-Tenon's injection, via ophthalmic drops, via ophthalmic gel, via ophthalmic ointment, via iontophoresis and via ocular implant and/or insert.
93. The pharmaceutical composition as recited in claim 91, wherein said therapeutically effective amount of combretastatin A4 prodrug is administered non-systemically to the eye of said subject in an amount of combretastatin A4 prodrug in the range of from approximately 0.1 mg/ml to approximately 100 mg/ml.
94. The pharmaceutical composition as recited in claim 91, wherein said therapeutically effective amount of combretastatin A4 prodrug is systemically administered to said subject.
95. The pharmaceutical composition as recited in claim 91, wherein said therapeutically effective amount of combretastatin A4 prodrug is administered systemically to said subject in an amount of combretastatin A4 prodrug in the range of from approximately 0.1 mg/m2 to approximately 120 mg/m2.
CA2453442A 2001-07-13 2002-07-15 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases Expired - Fee Related CA2453442C (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US38622701P 2001-07-13 2001-07-13
US60/386,227 2001-07-13
US37784702P 2002-05-03 2002-05-03
US37755602P 2002-05-03 2002-05-03
US37784502P 2002-05-03 2002-05-03
US60/377,845 2002-05-03
US60/377,847 2002-05-03
US60/377,556 2002-05-03
PCT/US2002/022449 WO2003006002A1 (en) 2001-07-13 2002-07-15 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases

Publications (2)

Publication Number Publication Date
CA2453442A1 true CA2453442A1 (en) 2003-01-23
CA2453442C CA2453442C (en) 2011-02-01

Family

ID=32034390

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2453442A Expired - Fee Related CA2453442C (en) 2001-07-13 2002-07-15 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases

Country Status (8)

Country Link
EP (1) EP1406600A4 (en)
JP (2) JP2004536847A (en)
KR (1) KR20040030042A (en)
CN (1) CN1527704B (en)
CA (1) CA2453442C (en)
NZ (1) NZ575466A (en)
WO (1) WO2003006002A1 (en)
ZA (1) ZA200400210B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229960A1 (en) * 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
JP4005048B2 (en) * 2003-04-09 2007-11-07 日信工業株式会社 Carbon fiber composite material and method for producing the same
WO2011003080A1 (en) * 2009-07-02 2011-01-06 Oxigene, Inc. Combretastatins for prevention of posterior capsule opacification
JP2013502440A (en) * 2009-08-27 2013-01-24 バイオノミックス リミテッド Treatment of macular degeneration
US9006284B2 (en) 2009-08-27 2015-04-14 Bionomics Limited Combination therapy for treating proliferative diseases
AP2015008241A0 (en) * 2012-08-02 2015-01-31 Amril Ag Natural rubber containing nanocarbon
CN113520995B (en) * 2021-08-16 2023-03-10 海南鑫开源医药科技有限公司 Ion-sensitive in-situ gel for eyes, and preparation method and application thereof
CN113577020B (en) * 2021-08-16 2022-09-23 海南鑫开源医药科技有限公司 Vitreous intracavity injection, preparation method and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338645C (en) * 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
WO1999035150A1 (en) * 1998-01-09 1999-07-15 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Synthesis of combretastatin a-4 prodrugs and trans-isomers thereo f
GB9903404D0 (en) * 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
AU776511B2 (en) * 1999-02-18 2004-09-09 Baylor University Compositions and methods for use in targeting vascular destruction
US6670344B2 (en) * 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts

Also Published As

Publication number Publication date
JP2009132738A (en) 2009-06-18
WO2003006002A8 (en) 2004-05-27
WO2003006002A1 (en) 2003-01-23
CA2453442C (en) 2011-02-01
ZA200400210B (en) 2005-06-29
EP1406600A4 (en) 2007-06-06
EP1406600A1 (en) 2004-04-14
JP2004536847A (en) 2004-12-09
NZ575466A (en) 2011-01-28
KR20040030042A (en) 2004-04-08
CN1527704B (en) 2011-05-18
CN1527704A (en) 2004-09-08
WO2003006002A9 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
Yeung et al. Cytotoxicity of triamcinolone on cultured human retinal pigment epithelial cells: comparison with dexamethasone and hydrocortisone
US10792288B2 (en) Preservative free brimonidine and timolol solutions
AU2011274245B2 (en) Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease
US10973758B2 (en) Methods of eye treatment using therapeutic compositions containing dipyridamole
JP2013535472A (en) Bimatoprost and timolol solution without preservatives
WO2023024126A1 (en) Voriconazole-containing ophthalmic gel, and preparation method therefor and use thereof
CA2453442A1 (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
MX2023009352A (en) Methods for ophthalmic delivery of roflumilast.
US20050031652A1 (en) Compositions and methods comprising memantine and polyanionic polymers
JP2004536847A5 (en)
EP4087533B1 (en) Soluble melatonin tripartate adduct for the prevention and treatment of rare and severe eye sight-threatening conditions and neuro-ophthalmic disorders
RU2004104337A (en) COMPOSITIONS AND METHODS FOR INTRODUCING TUBULIN BINDING MEDICINES FOR THE TREATMENT OF EYE DISEASES
US20040259844A1 (en) Method and composition for preventing, reducing and reversing ocular ischemic neuronal damage
WO2024135837A1 (en) Epinastine-containing aqueous composition for improving tissue transferability and preservative effect
CN112243375A (en) Methods of use and pharmaceutical compositions of selective SYK inhibitors
CN114072139A (en) Anesthetic composition and method of anesthetizing an eye

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170717